Nephron Research Adjusts Price Target on Stryker to $450 From $435
Needham Maintains Stryker Corp(SYK.US) With Buy Rating, Raises Target Price to $442
Stryker Is Maintained at Overweight by Wells Fargo
Stryker Analyst Ratings
RBC Capital Maintains Stryker Corp(SYK.US) With Buy Rating, Raises Target Price to $425
Citi Maintains Stryker Corp(SYK.US) With Buy Rating, Raises Target Price to $450
Wells Fargo Maintains Stryker Corp(SYK.US) With Buy Rating, Raises Target Price to $427
Stryker Raised to Overweight From Equal-Weight by Morgan Stanley
Stryker Analyst Ratings
Morgan Stanley Initiates Stryker Corp(SYK.US) With Buy Rating, Announces Target Price $445
Piper Sandler Maintains Stryker Corp(SYK.US) With Buy Rating, Maintains Target Price $420
BofA Securities Maintains Stryker Corp(SYK.US) With Buy Rating
Wells Fargo Maintains Stryker Corp(SYK.US) With Buy Rating, Maintains Target Price $405
Argus Adjusts Price Target on Stryker to $410 From $380
Morgan Stanley Maintains Stryker Corp(SYK.US) With Hold Rating, Raises Target Price to $370
Barclays Maintains Stryker Corp(SYK.US) With Buy Rating, Raises Target Price to $418
Citi Maintains Stryker Corp(SYK.US) With Buy Rating, Announces Target Price $411
Stryker Analyst Ratings
A Quick Look at Today's Ratings for Stryker Corp(SYK.US), With a Forecast Between $370 to $420
Stryker Is Maintained at Buy by Canaccord Genuity